Market capitalization | $2.99b |
Enterprise Value | $2.69b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 9.58 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-270.73m |
Free Cash Flow (TTM) Free Cash Flow | $-230.19m |
Cash position | $364.38m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
9 Analysts have issued a Scholar Rock Holding Corp. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.73 -1.73 |
62%
62%
|
|
EBITDA | -269 -269 |
46%
46%
|
EBIT (Operating Income) EBIT | -271 -271 |
43%
43%
|
Net Profit | -264 -264 |
44%
44%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | David Hallal |
Employees | 196 |
Founded | 2012 |
Website | www.scholarrock.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.